Considering Testosterone Therapy? What to Know Before You Begin

Symptoms and consistently low testosterone should be established before therapy is considered.

A single low testosterone result should generally not be the entire basis for starting therapy.

Current clinical guidance recommends evaluating symptoms and confirming consistently low testosterone with appropriately timed repeat testing.

If testosterone remains low, additional evaluation may be needed to help determine the cause.

That matters because testosterone deficiency can result from different conditions, and some contributing factors may be reversible or require separate treatment.

The goal should be to treat the patient — not simply correct one laboratory number.

Exogenous testosterone can suppress sperm production, making future fertility goals important.

This is one of the most important discussions to have before testosterone therapy begins.

Testosterone taken from outside the body can suppress the hormonal signals responsible for sperm production.

That means testosterone therapy can substantially reduce sperm counts and may impair fertility.

Men who may want biological children in the future should discuss those plans before starting treatment, even if pregnancy is not an immediate goal.

Other approaches may be considered in selected men when maintaining fertility is important.

This deserves a separate conversation because preserving fertility after treatment has begun can be more complicated than discussing it beforehand.

Potential benefits vary, and treatment is not a universal solution for midlife symptoms.

In men with appropriately diagnosed hypogonadism, testosterone therapy may improve certain symptoms or findings.

Sexual desire and sexual activity may improve in some men.

Treatment can also affect body composition, bone health, red blood cell production, and other physiological measures depending on the individual.

But testosterone therapy does not guarantee more energy, effortless weight loss, restored athletic performance, improved mood, or resolution of every sexual concern.

If poor sleep is driving fatigue, testosterone does not replace sleep treatment.

If cardiovascular or metabolic disease is contributing to erectile dysfunction, testosterone does not replace evaluation of those conditions.

And if a symptom does not improve despite appropriately managed testosterone levels, that is useful information.

It may mean another cause needs attention.

Follow-up helps assess response, testosterone levels, blood counts, blood pressure, and safety.

Testosterone therapy changes physiology, which is why follow-up matters.

Healthcare professionals may monitor testosterone levels, symptoms, treatment response, blood counts, blood pressure, prostate-related considerations when appropriate, and other measures based on the patient and treatment being used.

One particularly important concern is an excessive increase in red blood cell concentration, sometimes called erythrocytosis or polycythemia.

Blood pressure also deserves attention because testosterone products can increase blood pressure.

Monitoring is not simply paperwork attached to a prescription.

It is part of the treatment.

Newer evidence adds reassurance while blood-pressure and individual cardiovascular factors still matter.

Testosterone and cardiovascular risk have been debated for years.

Large clinical trial data have helped answer part of that question.

The TRAVERSE trial, which included more than 5,000 men with hypogonadism and cardiovascular disease or elevated cardiovascular risk, did not show a meaningful increase in major cardiovascular events such as cardiovascular death, heart attack, or stroke with testosterone compared with placebo during the trial period.

That evidence led FDA to remove earlier boxed-warning language about increased cardiovascular event risk from testosterone product labeling.

But that does not mean testosterone therapy is risk-free.

FDA-required blood-pressure studies demonstrated increases in blood pressure across testosterone products, leading to class-wide labeling warnings.

Other potential risks and longer-term questions remain important.

The useful conclusion is not that testosterone is either “dangerous” or “completely safe.”

It is that treatment decisions should be based on current evidence and the individual patient.

Age, symptoms, history, and risk help determine appropriate prostate assessment and follow-up.

Testosterone therapy has a complicated history in discussions about prostate health.

Current evidence has changed some older assumptions, but prostate-related evaluation and monitoring remain part of responsible testosterone care.

A healthcare professional may consider age, symptoms, personal and family history, prostate-specific antigen testing when appropriate, and other factors before and during treatment.

Men with known or suspected prostate cancer require individualized medical evaluation before testosterone therapy is considered.

The appropriate monitoring plan depends on the individual rather than a one-size-fits-all schedule.

The goal is appropriate treatment response and safety, not maximizing a laboratory value.

The goal of testosterone replacement therapy is not to push testosterone as high as possible.

Higher numbers do not automatically produce better health.

Treatment should aim to address clinically meaningful testosterone deficiency while minimizing unnecessary exposure and adverse effects.

Response should therefore be evaluated in more than one way.

Are the symptoms being treated actually improving?

Are testosterone levels in an appropriate range?

Are blood counts and blood pressure acceptable?

Have new side effects appeared?

Have fertility goals changed?

Does treatment still make sense?

Those questions matter more than chasing a particular number.